5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule that blocks nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat-cell metabolism. It is not a peptide. It has been studied only in cells and mice and is not approved for human use.
Also known as: 5-amino-1-methylquinolinium, NNMT inhibitor.
For 5-amino-1MQ, there is no approved product and no published human study, so there are no label strengths or studied human amounts.
5-Amino-1MQ is not FDA approved, and we could not find any published study that gave it to people.
In a 2018 study (Neelakantan), a potent methylquinolinium NNMT inhibitor, the chemical family 5-amino-1MQ belongs to, lowered body weight, white fat mass and plasma cholesterol in mice on a high-fat diet without changing how much they ate. In a 2024 study (Babula), 5-amino-1MQ given once a day for 28 days to obese mice limited weight and fat gain and improved glucose tolerance, insulin sensitivity and fatty liver. The 2024 paper states that its authors include the founder and current or former employees of Ridgeline Therapeutics. Mouse results often do not carry over to people.
We could not find a published human half-life. The 2024 mouse study (Babula) measured blood levels after dosing into a vein, by mouth and under the skin in mice; animal numbers do not carry over to people, so we do not list one here.
How Dose Track handles peptides · Reconstitution calculator · Half-life calculator